echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > JAMA: The effect of infliximab active therapeutic drug monitoring program on the clinical remission rate of patients with immune-mediated inflammatory diseases

    JAMA: The effect of infliximab active therapeutic drug monitoring program on the clinical remission rate of patients with immune-mediated inflammatory diseases

    • Last Update: 2021-05-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Tumor necrosis factor (TNF) inhibitors represented by infliximab can treat many chronic immune- mediated inflammatory diseases, such as rheumatoid arthritis , spondyloarthritis, psoriatic arthritis, medsci.


    Immune Rheumatoid Arthritis and medsci.


    The study was carried out in 21 Norwegian hospitals.


    The average age of the patients was 44.


    100 of the 198 patients in the TDM group (50.


    For patients with immune-mediated inflammatory diseases treated with infliximab, compared with standard treatment, the active therapeutic drug monitoring program did not significantly improve the clinical remission rate of patients within 30 weeks .


    For patients with immune-mediated inflammatory diseases treated with infliximab, compared with standard treatment, the active therapeutic drug monitoring program did not significantly improve the clinical remission rate of patients within 30 weeks .


    Original source

    Silje Watterdal Syversen et al.


    com/journals/jama/article-abstract/2779549" target="_blank" rel="noopener">Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases A Randomized Clinical Trial.
    JAMA

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.